uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2009 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 20, no 6, 1057-1061 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: To evaluate [(18)F]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), for early evaluation of response to palliative chemotherapy and for prediction of long-term outcome, in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: In a randomized trial, patients with mCRC received irinotecan-based combination chemotherapy. FDG-PET was carried out before treatment and after two cycles in 51 patients at two centers. Visual changes in tumor FDG uptake and changes measured semi-automatically, as standard uptake values (SUVs), were compared with radiological response after four and eight cycles. RESULTS: The mean baseline SUV for all tumor lesions per patient was higher in nonresponders than in responders (mean 7.4 versus 5.6, P = 0.02). There was a strong correlation between metabolic response (changes in SUV) and objective response (r = 0.57, P = 0.00001), with a sensitivity of 77% and a specificity of 76%. There was no significant correlation between metabolic response and time to progression (P = 0.5) or overall survival (P = 0.1). CONCLUSIONS: Although metabolic response assessed by FDG-PET reflects radiological tumor volume changes, the sensitivity and specificity are too low to support the routine use of PET in mCRC. Furthermore, PET failed to reflect long-term outcome and can, thus, not be used as surrogate end point for hard endpoint benefit.

Place, publisher, year, edition, pages
2009. Vol. 20, no 6, 1057-1061 p.
Keyword [en]
colorectal cancer, FDG-PET, palliative chemotherapy, prediction, response evaluation
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-105342DOI: 10.1093/annonc/mdn744ISI: 000266343900014PubMedID: 19164458OAI: oai:DiVA.org:uu-105342DiVA: diva2:221160
Available from: 2009-06-03 Created: 2009-06-03 Last updated: 2014-09-08Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Garske, Ulrike GarskeSundin, Anders
By organisation
Department of Oncology, Radiology and Clinical ImmunologyDepartment of Medical SciencesRadiology
In the same journal
Annals of Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 209 hits
ReferencesLink to record
Permanent link

Direct link